NCT04539938 2026-03-23
HER2CLIMB-04
Seagen Inc.
Phase 2 Completed
Clinical Trials
11 trialsNCT03523585 2026-02-27
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Daiichi Sankyo
Phase 3 Completed
NCT06386263 2025-10-15
HER-TEMPO
AstraZeneca
Completed
NCT06504719 2025-09-15
Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan
Hellenic Cooperative Oncology Group
Completed
NCT04420598 2025-06-24
DEBBRAH
MedSIR
Phase 2 Completed
NCT04132960 2025-06-12
DAISY
UNICANCER
Phase 2 Completed
NCT03523572 2025-01-27
Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer
Daiichi Sankyo
Phase 1 Completed
NCT05458401 2024-03-15
EUROPA T-DXd
Daiichi Sankyo
Completed
NCT04752059 2023-05-12
TUXEDO-1
Medical University of Vienna
Phase 2 Completed
NCT03368196 2022-11-03
DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein
Daiichi Sankyo
Phase 1 Completed
NCT03366428 2022-04-12
Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer
Daiichi Sankyo
Phase 1 Completed